AIM Vaccine Co. Ltd. (6660) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of AIM Vaccine Co. Ltd. stock HK$1.01, price HK$1.50, that is 32.4% below the price, quality 31 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
AIM Vaccine Co. Ltd.
6660 · HKExpensive (fair value 32% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
49‑month range HK$1.39 – HK$58.65 · fair‑value band HK$0.7500 – HK$1.51 · the HK$1.50 price screens above the HK$1.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 12, 2026.
Every Wednesday you see whether AIM Vaccine Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People's Republic of China and internationally.
Show moreShow less
The company's product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection.
It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine.
In addition, the company develops 20-valent and 24-valent pneumonia conjugate vaccine, haemophilus influenzae type b conjugate vaccine, absorbed tetanus vaccine, quadrivalent influenza virus vaccine (MDCK Cells), and human diploid rabies vaccine.
Further, it offers hexavalent meningococcal vaccine to treat meningococcal disease; hexavalent group b streptococcus polysaccharide conjugate vaccine; mRNA human rabies vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; diphtheria, tetanus, pertussis and haemophilus influenzae type b, and acellular pertussis combination vaccine for the treatment of DTP; and recombinant group B meningococcal vaccine to treat meningococcal disease.
The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. The company was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.
Stock analysis
AIM Vaccine Co. Ltd. (6660) currently trades at HK$1.50, while our model-based Fair Value estimate is HK$1.01, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 89/100, which puts the data coverage at low.
Scenario range: HK$0.7500 (bear) to HK$1.51 (bull), the price of HK$1.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
AIM Vaccine Co. Ltd. reported revenue of 1.2B CNY in FY2025 versus 1.6B CNY in FY2021, a compound −7.2%/yr. Reported net income was −675M CNY in FY2025.
Key figures
Market cap HK$1.8B (≈ $234M) Micro · P/S ratio 1.86 · Net margin −57.9% · Return on equity −23.2% · Return on assets (EBIT) −13.3% (5-year average) · Operating margin −32.8% · Revenue (TTM) 1.0B CNY · Revenue growth (YoY) −31.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 60% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −32%, 6660 screens richer than that median.
Fair Value models
All 1 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare AIM Vaccine Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 6660 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 6660 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 6660 |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs 6660 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 6660 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 6660 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 6660 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 6660 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 6660 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 6660 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is AIM Vaccine Co. Ltd. (6660) overvalued or undervalued?
What is the fair value of 6660?
What is the quality score of 6660?
What is the price target for AIM Vaccine Co. Ltd. (6660)?
What is the AIM Vaccine Co. Ltd. stock forecast for 2026?
What is the revenue of AIM Vaccine Co. Ltd. (6660)?
What is the intrinsic value of AIM Vaccine Co. Ltd. (6660)?
Is AIM Vaccine Co. Ltd. stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 6660?
How much is AIM Vaccine Co. Ltd. worth?
What do the bullish and bearish scenarios say about 6660?
How solid is the balance sheet of AIM Vaccine Co. Ltd. (6660)?
How far is 6660 from its 52-week high?
Which stocks are comparable to AIM Vaccine Co. Ltd.?
Is AIM Vaccine Co. Ltd. stock attractive at the current price?
How is the fair value of 6660 calculated?
Is it still worth investing in stocks now?
What is the share price of AIM Vaccine Co. Ltd. (6660)?
What should I pay attention to with AIM Vaccine Co. Ltd. right now?
Key figures of AIM Vaccine Co. Ltd.
How large is the market capitalisation of AIM Vaccine Co. Ltd. (6660)?
What is the P/S ratio of AIM Vaccine Co. Ltd. (6660)?
What is the net margin of AIM Vaccine Co. Ltd. (6660)?
What is the return on equity of AIM Vaccine Co. Ltd. (6660)?
What is the EBIT return on assets of AIM Vaccine Co. Ltd. (6660)?
What is the operating margin of AIM Vaccine Co. Ltd. (6660)?
How fast is revenue growing at AIM Vaccine Co. Ltd. (6660)?
How much free cash flow does AIM Vaccine Co. Ltd. (6660) generate?
How much net debt does AIM Vaccine Co. Ltd. (6660) carry?
Watch AIM Vaccine Co. Ltd. in the live analysis
One click puts AIM Vaccine Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.